Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Iambic Therapeutics
Iambic Therapeutics to Present at the 43rd Annual JP Morgan Healthcare Conference
December 18, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces Appointment of Peter Olson, Ph.D., as Chief Scientific Officer
December 11, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery
October 29, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Named to the Endpoints 11 List of Biotech’s Most Promising Startups
September 27, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to Its Board of Directors
September 05, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs
June 18, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
May 23, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of Both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
March 28, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
March 27, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures
February 12, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Expands Leadership Team With the Appointment of Neil Josephson, MD as Chief Medical Officer
February 09, 2024
From
Iambic Therapeutics
Via
Business Wire
Iambic Therapeutics Announces Close of Oversubscribed $100 Million Series B Financing to Advance AI-Discovered Therapeutics into Clinical Development and Enters Collaboration with NVIDIA
October 03, 2023
From
Iambic Therapeutics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.